Outlook 2021: Medtechs Must Look To Late 2021 And 2022 For A Return To Normal Times
Medtech is as attractive as it has ever been says Jefferies Healthcare
Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.
You may also be interested in...
The company is recalling all unused Lotus Edge inventory and will stop developing the Lotus platform while shifting resources to support its Acurate neo2 transcatheter aortic valve system. The decision will cost the company up to $300m.
Royal Philips closed out the first year of COVID-19 with 7% revenue growth in the fourth quarter. CEO Frans van Houten says low single digit growth is the target for fiscal 2021.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.